- Home
- ACLS vs HCM Comparison
ACLS vs HCM Comparison
Compare ACLS & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACLS | HCM |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 2.6B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACLS | HCM |
|---|---|---|
| Price | $139.77 | $13.42 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 4 | 1 |
| Target Price | ★ $101.50 | $13.75 |
| AVG Volume (30 Days) | ★ 642.8K | 28.6K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.80 | N/A |
| Revenue | ★ $839,048,000.00 | N/A |
| Revenue This Year | $1.93 | $20.60 |
| Revenue Next Year | $7.91 | $15.62 |
| P/E Ratio | $34.97 | ★ $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.46 | $13.06 |
| 52 Week High | $147.94 | $19.50 |
Technical Indicators
Market Signals| Indicator | ACLS | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 74.72 | 34.64 |
| Support Level | $78.24 | $13.08 |
| Resistance Level | N/A | $15.59 |
| Average True Range (ATR) | 6.64 | 0.42 |
| MACD | 0.73 | -0.23 |
| Stochastic Oscillator | 78.72 | 8.95 |
Price Performance
Historical ComparisonAbout ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.